Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: Preliminary observations☆,☆☆,★,★★
Section snippets
Patients
This study was approved by the West Virginia University Institutional Review Board for the Protection of Human Subjects; written, informed consent was ob tained from all subjects or their parents before study enrollment. All of the patients enrolled in this study had a sweat chloride concentration >60 mmol/L, either a family history or medical history compatible with CF, and documented respiratory colonization with P. aeruginosa antedating enrollment by at least 1 year. Patients who were
RESULTS
Twenty-two patients from the Mountain State Cystic Fibrosis Center fulfilled entry criteria. Two patients declined enrollment. Of the 20 patients who gave signed informed consent, 4 were dropped from the study: 2 patients failed to return as scheduled for the second pretherapy visit and 2 patients were noncompliant with drug therapy and follow-up visits. Of the remaining 16 patients, 7 were assigned to the control group and 9 to the treatment group (Table I). The two groups were similar in
DISCUSSION
Chronic pseudomonal endobronchitis leading to progressive pulmonary deterioration and ultimately to respiratory failure is the principal cause of morbidity and death in patients with CF.1 Baltimore et al.21 demonstrated that in lungs affected by CF, P. aeruginosa was found almost exclusively in the endobronchium, along with profound inflammation. Neutrophils are the predominant cell type found in CF sputa.22, 23, 24 Suter et al.4 demonstrated that sputum from Pseudomonas-infected patients with
References (29)
The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis
J PEDIATR
(1981)- et al.
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis
J PEDIATR
(1988) Determination of oxpentifylline and three metabolites in plasma by automated capillary gas chromatography using nitrogen selective detection
J Chromatogr
(1987)A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding
Anal Biochem
(1976)- et al.
Aerosol α1-antitrypsin treatment for cystic fibrosis
Lancet
(1991) - et al.
Oxpentoxifylline in endotoxaemia
Lancet
(1989) - et al.
Cystic fibrosis
Inflammation in the lung cystic fibrosis-A vicious cycle that does more harm than good?
Clin Rev Allergy
(1991)- et al.
Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis
J Infect Dis
(1984) - et al.
Proteins of the cystic fibrosis respiratory tract: fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis
J Clin Invest
(1984)
Complement receptor expression on neutrophils at an inflammatory site, the pseudomonas infected cystic fibrosis lung
J Clin Invest
Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa
J Infect Dis
Relation between tumor necrosis factor-alpha and granulocyte elastase-α1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis
Am Rev Resp Dis
Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections
Am Rev Resp Dis
Cited by (23)
Newer therapies for cystic fibrosis
2000, Paediatric Respiratory ReviewsInflammation in cystic fibrosis and its management
2000, Paediatric Respiratory ReviewsTherapies aimed at airway inflammation in cystic fibrosis
1998, Clinics in Chest MedicineIntralesional pentoxifylline, triamcinolone acetonide, and their combination for treatment of keloid scars
2021, Journal of Cosmetic DermatologyAntiinflammatory therapies for cystic fibrosis: Past, present, and future
2005, Pharmacotherapy
- ☆
From the Department of Pediatrics, West Virginia University School of Medicine, Morgantown, and Hoechst-Roussel Pharmaceuticals, Inc., Somerville, New Jersey.
- ☆☆
Supported by grants from Hoechst-Roussel Pharmaceuticals, Inc., and the Cystic Fibrosis Foundation.
- ★
Reprint requests: Stephen C. Aronoff, MD, Department of Pediatrics, West Virginia University School of Medicine, Health Science Center, Morgantown, WV 26506.
- ★★
0022-3476/94/$3.00 + 0 9/25/59056